US EditionHelix Releases PGx Tests For Use In Neurology And Oncology - Data Intelligence
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Helix Releases PGx Tests For Use In Neurology And Oncology - Data Intelligence
The latest PGx tests encompass medications for cancer, cardiovascular diseases, pain management, gastrointestinal conditions, and anaesthesia guidance. Credit: Katy Pack / Shutterstock. US-based genomics company Helix has released a new suite of pharmacogenomics (PGx) tests, widening its portfolio to offer personalised patient care in neurology and oncology. The suite includes a PGx Fluoropyrimidines DPYD test to detect individuals with dihydrop…
Helix releases pharmacogenomics tests for use in neurology and oncology
Helix has released a new suite of pharmacogenomics (PGx) tests, widening its portfolio in neurology and oncology.The post Helix releases pharmacogenomics tests for use in neurology and oncology appeared first on Medical Device Network.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
